Startups
Enzyre is a UMC St. Radboud spin-off company which officially started in March 2017. It was founded with the mission to develop innovative diagnostic solutions to enable personalized medicine. The company holds the vision to create a point of care (POC) diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.
Overview
Location
Netherlands, Gelderland, Nijmegen
Employees
11-50
Total raised
$13.53M
Founded date
2016
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 6, 2022 | Takeda Ventures | takeda.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jul 27, 2020 | Funding round | $1.65M |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 4, 2022 | i&i Biotech Fund investoval více než 1 milion eur do unikátní diagnostické technologie pro testování srážlivosti krve | Firma Enzyre je šestou společností, kterou pomohl fond i&i Biotech Fund od svého založení v srpnu 2021 svými investicemi podpořit. Více na www.inibio.eu. Jsme nadšeni, že můžeme společnost Enzyre doprovázet při vývoji tak slibné inovati... |
| Nov 3, 2022 | Dutch-based Enzyre bags €12.2M to develop diagnostic device for haemophilia patients | Nijmegen, the Netherlands-based Enzyre, a Radboud University Medical Center spin-out, announced on Wednesday, November 2, that it has secured $12M (approximately €12.2M) in a Series A round of funding. The round was led by new investor Oost... |
| Nov 3, 2022 | Netherlands-based diagnostic technology platform startup Enzyre raises EUR 12 million in Series A funding | NIJMEGEN, the Netherlands, November 2, 2022 — Enzyre, which is developing ground-breaking ambulant diagnostic technology for blood coagulation testing, announced today that it had raised EUR 12 million in a Series A financing led by new inv... |
| Nov 2, 2022 | Enzyre Closes EUR12M Series A Financing | Enzyre, a Nijmegen, Netherlands-based provider of ambulant diagnostic technology for blood coagulation testing, raised €12M in Series A funding. The round was led by Oost NL, with participation from i&i Biotech Fund, Demcon Investment, ... |
| Jul 28, 2020 | This Dutch startup is developing Enzypad to bring the lab to haemophilia patients, bags €1.4M funding | Based out of Nijmegen, The Netherlands, Enzyre is a spin-out from Radboud University Medical Center, developing Enzypad, a near-patient diagnostic and monitoring device initially focused on blood coagulation. Raised €1.4M Corona Bridge Loan... |
| Jul 27, 2020 | Enzyre Receives €1.4M Corona Bridge Loan | Enzyre, a Nijmegen, The Netherlands-based developer of diagnostic technology, received a €1.4m Corona Bridge Loan. Novalis Biotechnology Incubation, through its seed fund, participated as co-financer in the loan, which was granted by the Du... |
| Enzyre | “Enzyre - Near Patient Diagnostics Focused on Blood Coagulation” |
Reviews 0
FAQ about Enzyre B.V.
When was Enzyre B.V. founded?
Enzyre B.V. was founded in 2016.
How much funding has Enzyre B.V. raised?
Enzyre B.V. has raised $13.53M in total across 2 funding rounds.
What funding rounds has Enzyre B.V. raised?
Parsers VC lists 2 funding rounds of Enzyre B.V., among them a funding round of $1.65M on Jul 27, 2020.
Who has invested in Enzyre B.V.?
Parsers VC lists 2 investors of Enzyre B.V., among them Takeda Ventures.
What has the press written about Enzyre B.V.?
Parsers VC has collected 8 articles mentioning Enzyre B.V., among them “i&i Biotech Fund investoval více než 1 milion eur do unikátní diagnostické technologie pro testování srážlivosti krve” (Nov 4, 2022) and “Dutch-based Enzyre bags €12.2M to develop diagnostic device for haemophilia patients” (Nov 3, 2022).
Is Enzyre B.V. still active?
Yes, Enzyre B.V. is active; its latest activity on Parsers VC dates from Nov 4, 2022.